Research programme: fibroblast growth factor antagonists - Encysive

Drug Profile

Research programme: fibroblast growth factor antagonists - Encysive

Latest Information Update: 23 Aug 2006

Price : $50

At a glance

  • Originator Encysive Pharmaceuticals
  • Class
  • Mechanism of Action Fibroblast growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronary artery restenosis

Most Recent Events

  • 23 Aug 2006 Discontinued - Preclinical for Coronary artery restenosis in USA (unspecified route)
  • 06 Jun 2006 No development reported - Preclinical for Coronary artery restenosis in USA (unspecified route)
  • 21 May 2003 Texas Biotechnology Corporation is now called Encysive Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top